Special Issue

Drug Development in Children: Clinical Advances and Perspectives

Message from the Guest Editors

The lack of progress in drug development for children is a common issue worldwide. Children respond to pharmaceuticals differently from adults in more than a few cases, with wide variation from neonates to adolescents, requiring responses and studies appropriate to each age group, including in terms of pharmaceutical dosage forms and pharmacokinetics. In addition, there are few opportunities to collect information on pediatric patients, and there is a lack of evidence. In order to assess risks and benefits based on medical and pharmacological evidence, ICH Guideline E11 (Guidance on Clinical Studies of Medicinal Products in Pediatric Populations) and E11(R1) recommend the use of optimal methods for collecting information on pediatric experiences. We would like to collect and share the latest findings of clinical research, regulatory science, investigations of clinical issues, pediatric formulation development, and the off-label use of drugs in children, as well as a wide range of recommendations related to issues of children, in order to make further progress in drug development.

Guest Editors

Dr. Akimasa Yamatani

Pediatric and Perinatal Pharmacology, Meiji Pharmaceutical University, Tokyo 204-8588, Japan

Dr. Jumpei Saito

Department of Pharmacy, National Center for Child Health and Development, 2-10-1, Okura, Setagayaku, Tokyo 157-8535, Japan

Deadline for manuscript submissions

closed (10 September 2024)



Children

an Open Access Journal by MDPI

Impact Factor 2.1
CiteScore 3.8
Indexed in PubMed



mdpi.com/si/196954

Children
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
children@mdpi.com

mdpi.com/journal/children





Children

an Open Access Journal by MDPI

Impact Factor 2.1 CiteScore 3.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or comprehensive review for consideration and publication in *Children* (ISSN 2227-9067). *Children* is an open access journal—research articles, reviews, and other content are published online immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. The journal focuses on sharing clinical, epidemiological, and translational science relevant to children's health. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Paul R. Carney

Departments of Child Health and Neurology, University of Missouri, 400 Keene Street, Columbia, MO 65211, USA

Author Benefits

Open Access

 free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q2 (Pediatrics) / CiteScore - Q2 (Pediatrics, Perinatology and Child Health)

